生物类似药治疗剂：生物等效性和免疫原性问题 - Suppr

Suppr

超能文献

Biosimilar therapeutic agents: issues with bioequivalence and immunogenicity.

作者信息

Schellekens H

出版信息

Eur J Clin Invest. 2004 Dec;34(12):797-9. doi: 10.1111/j.1365-2362.2004.01428.x.

DOI:10.1111/j.1365-2362.2004.01428.x

PMID:15606720

Abstract

摘要

相似文献

Eur J Clin Invest. 2004 Dec;34(12):797-9. doi: 10.1111/j.1365-2362.2004.01428.x.

Bioequivalence and interchangeability of narrow therapeutic range drugs. Canadian Society for Pharmaceutical Sciences discussion.

J Pharm Pharm Sci. 1998 Jan-Apr;1(1):2-7.

The end of the beginning?

Nat Biotechnol. 2006 Apr;24(4):367. doi: 10.1038/nbt0406-367.

Evaluation of generic drugs in Spain.

Methods Find Exp Clin Pharmacol. 1998;20 Suppl A:3.

Assessing the bioequivalence of biosimilars The Retacrit case.

Drug Discov Today. 2009 May;14(9-10):495-9. doi: 10.1016/j.drudis.2009.02.003. Epub 2009 Feb 14.

G Ital Nefrol. 2008 May-Jun;25(3):275.

Lakartidningen. 2009;106(23):1563-6.

Generics and substitution modalities: proposed methods for the evaluation of equivalence, traceability and pharmacovigilance reporting.

Therapie. 2008 Jul-Aug;63(4):301-9. doi: 10.2515/therapie:2008047. Epub 2008 Oct 22.

Batch-to-Batch and Within-Subject Variability: What Do We Know and How Do These Variabilities Affect Clinical Pharmacology and Bioequivalence?

Clin Pharmacol Ther. 2019 Feb;105(2):326-328. doi: 10.1002/cpt.1294. Epub 2019 Jan 16.

The therapeutic equivalence of complex drugs.

Regul Toxicol Pharmacol. 2011 Feb;59(1):176-83. doi: 10.1016/j.yrtph.2010.09.021. Epub 2010 Oct 14.

引用本文的文献

From Basic Immunology to Clinical Practice: Bio-Originators versus Bio-Similars.

Mediterr J Rheumatol. 2019 May 31;30(Suppl 1):54-58. doi: 10.31138/mjr.30.1.54. eCollection 2019 Jun.

Position of Scientific Oncological Societies Towards Biosimilar Antibodies.

Breast Care (Basel). 2019 Mar;14(1):5-8. doi: 10.1159/000495145. Epub 2019 Jan 15.

Drugs. 2011 Aug 20;71(12):1527-36. doi: 10.2165/11593730-000000000-00000.

Through the looking glass: the protein science of biosimilars.

Clin Exp Nephrol. 2007 Sep;11(3):191-195. doi: 10.1007/s10157-007-0487-2. Epub 2007 Sep 28.

Biosimilars: recent developments.

Int Urol Nephrol. 2007;39(1):261-6. doi: 10.1007/s11255-006-9167-5. Epub 2007 Feb 27.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Eur J Clin Invest. 2004 Dec;34(12):797-9. doi: 10.1111/j.1365-2362.2004.01428.x.

Bioequivalence and interchangeability of narrow therapeutic range drugs. Canadian Society for Pharmaceutical Sciences discussion.

J Pharm Pharm Sci. 1998 Jan-Apr;1(1):2-7.

The end of the beginning?

Nat Biotechnol. 2006 Apr;24(4):367. doi: 10.1038/nbt0406-367.

Evaluation of generic drugs in Spain.

Methods Find Exp Clin Pharmacol. 1998;20 Suppl A:3.

Assessing the bioequivalence of biosimilars The Retacrit case.

Drug Discov Today. 2009 May;14(9-10):495-9. doi: 10.1016/j.drudis.2009.02.003. Epub 2009 Feb 14.

G Ital Nefrol. 2008 May-Jun;25(3):275.

Lakartidningen. 2009;106(23):1563-6.

Generics and substitution modalities: proposed methods for the evaluation of equivalence, traceability and pharmacovigilance reporting.

Therapie. 2008 Jul-Aug;63(4):301-9. doi: 10.2515/therapie:2008047. Epub 2008 Oct 22.

Batch-to-Batch and Within-Subject Variability: What Do We Know and How Do These Variabilities Affect Clinical Pharmacology and Bioequivalence?

Clin Pharmacol Ther. 2019 Feb;105(2):326-328. doi: 10.1002/cpt.1294. Epub 2019 Jan 16.

The therapeutic equivalence of complex drugs.

Regul Toxicol Pharmacol. 2011 Feb;59(1):176-83. doi: 10.1016/j.yrtph.2010.09.021. Epub 2010 Oct 14.

引用本文的文献

From Basic Immunology to Clinical Practice: Bio-Originators versus Bio-Similars.

Mediterr J Rheumatol. 2019 May 31;30(Suppl 1):54-58. doi: 10.31138/mjr.30.1.54. eCollection 2019 Jun.

Position of Scientific Oncological Societies Towards Biosimilar Antibodies.

Breast Care (Basel). 2019 Mar;14(1):5-8. doi: 10.1159/000495145. Epub 2019 Jan 15.

Drugs. 2011 Aug 20;71(12):1527-36. doi: 10.2165/11593730-000000000-00000.

Through the looking glass: the protein science of biosimilars.

Clin Exp Nephrol. 2007 Sep;11(3):191-195. doi: 10.1007/s10157-007-0487-2. Epub 2007 Sep 28.

Biosimilars: recent developments.

Int Urol Nephrol. 2007;39(1):261-6. doi: 10.1007/s11255-006-9167-5. Epub 2007 Feb 27.